For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) ...

Case in point: On Monday, a Portland, Oregon, jury awarded $260 million to a 49-year-old woman who claimed that more than 30 years of use of Johnson’s Baby Powder caused her mesothelioma.

After Amarin's tussle with investor group Sarissa Capital led to a restructuring and a board shuffle, the struggling drugmaker is undergoing its third CEO shake-up in just over a year.

Biogen is hoping to make the skies a bit more friendly to all airline passengers. | Biogen is hoping to make the skies a bit more friendly to all airline passengers.

In draft guidance issued Tuesday, NICE signed off on Lilly’s tirzepatide to help adults manage overweight and obesity alongside a change in diet and exercise. The endorsement paves the way for ...

Otsuka and Lundbeck want bipolar I patients to know longer-acting therapies can change their lives. | Otsuka and Lundbeck want bipolar I patients to know longer-acting therapies can change their lives ...

Announced during the American Society of Clinical Oncology (ASCO) annual cancer conference in Chicago this month, the two ...

Following fellow immunotherapy regimens by Roche and AstraZeneca, Bristol Myers Squibb’s Opdivo and Yervoy want to carve out a piece of the first-line liver cancer market, too. The BMS immunotherapy ...

In the field of anti-CD38 treatment for multiple myeloma, Johnson & Johnson’s Darzalex casts a long shadow. Now, Sanofi hopes ...

RYZ101 and the rest of RayzeBio’s platform leverages an alpha-emitting isotope called actinium-225 (Ac225). The approach ...

South Korean CDMO Lotte Biologics and Merck KGaA have signed a partnership deal focused on expanding biopharmaceutical ...

On the eve of the American Society of Clinical Oncology’s annual meeting last week, a piece of news set off vigorous ...